February 26, 2025

Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.

Conexiant

April 02, 2025

GLP-1 RAs Evaluated for Long-Term Risk of NAION in Patients With Diabetes

Researchers’ subgroup analyses provide data on increased risks according to timepoint, demographics, and comorbidities.

Conexiant

June 27, 2025

Also in the News…

The Ophthalmologist brings you the top news stories and studies of the week

The Ophthalmologist

August 04, 2025

Keeping an Eye on Blood Sugar Status

Researchers advocate for proactive diabetes management that protects ocular health beyond retinopathy prevention

The Ophthalmologist

August 05, 2025

Large US Study Adds to Connection Between NAION Risks and GLP-1 Drugs

Semaglutide and liraglutide showed the highest risk, while dulaglutide and exenatide were not significantly associated with NAION.

Ophthalmology Management

November 08, 2024

Is Intravenous Methylprednisolone Efficacious for Visual Complications of GCA?

While timely treatment is essential to protect vision, the researchers found no visual acuity benefit with IVMP.

Conexiant

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

November 07, 2024

Diabetes Affects 1 in 6 US Adults: CDC Data

In a stark reflection of diabetes screening gaps, more than one-quarter of U.S. adults with diabetes remained undiagnosed in 2021-2023, with obesity linked to a nearly four-fold higher prevalence compared to normal-weight individuals.

Conexiant

July 03, 2024

Semaglutide Linked to Vision-Threatening Eye Disorder

New study finds that 8.9% of type 2 diabetes patients taking semaglutide experienced NAION, compared to 1.8% of those on non-GLP-1 diabetes drugs.

Reuters